再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

未开盘 04-30 16:00:00 EDT

21.64

+0.89

+4.29%

盘后21.64

+0.000.00%

19:58 EDT

最高21.74	最低21.04	成交量26.64万
今开21.07	昨收20.75	日振幅3.37%
总市值24.31亿	流通市值23.67亿	总股本1.12亿
成交额574.45万	换手率0.24%	流通股本1.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":21.64,"timestamp":1777579200000,"preClose":20.75,"halted":0,"volume":266449,"hourTrading":{"tag":"盘后","latestPrice":21.64,"preClose":21.64,"latestTime":"19:58 EDT","volume":4374,"amount":94653.36,"timestamp":1777593517665,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.04289156626506027,"floatShares":109371942,"shares":112353700,"eps":-1.602622,"marketStatus":"未开盘","change":0.89,"latestTime":"04-30 16:00:00 EDT","open":21.07,"high":21.74,"low":21.04,"amount":5744505.6168060005,"amplitude":0.033735,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.602622,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1777622400000},"marketStatusCode":0,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":20.75,"preHourTrading":{"tag":"盘前","latestPrice":21.2,"preClose":20.75,"latestTime":"09:06 EDT","volume":2451,"amount":51434.29137300001,"timestamp":1777554410853,"change":0.45,"changeRate":0.021687,"amplitude":0.026988},"postHourTrading":{"tag":"盘后","latestPrice":21.64,"preClose":21.64,"latestTime":"19:58 EDT","volume":4374,"amount":94653.36,"timestamp":1777593517665,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.40498,"impliedVol":0.5808,"impliedVolPercentile":0.4},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"1170693892","title":"财报前瞻｜再鼎医药营收预计下滑0.50%，机构观点偏多","url":"https://stock-news.laohu8.com/highlight/detail?id=1170693892","media":"财报Agent","labels":["earningPreview"],"top":1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170693892?lang=zh_cn&edition=full","pubTime":"2026-04-30 15:32","pubTimestamp":1777534378,"startTime":"0","endTime":"0","summary":"再鼎医药将于2026年05月07日美股盘前发布最新季度财报，市场聚焦营收变动、利润曲线与关键管线推进节奏。市场一致预期本季度再鼎医药营收为1.13亿美元，同比下降0.50%；调整后每股收益预计为-0.50美元，同比改善9.62%。结合2026年05月07日的财报披露节点，机构普遍将本季度检验点聚焦于收入韧性、费用效率与DLL3临床推进的具体说明，整体倾向认为在基本面催化与管线价值共振下，估值具备进一步重估空间。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜再鼎医药营收预计下滑0.50%，机构观点偏多","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630589301","title":"再鼎医药(ZLAB)逆势上涨2.66% 机构指Zoci数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2630589301","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630589301?lang=zh_cn&edition=full","pubTime":"2026-04-28 23:20","pubTimestamp":1777389610,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药 逆势上涨2.66%，最新报22.44美元，成交额309.77万美元。机构维持2026年和2027年盈利预测不变，维持跑赢行业评级，且由于Zoci数据积极，机构上调Zoci未来销售峰值，基于DCF模型，上调H股/US股目标价15%/15%至22.0港元/28.4美元，较当前股价有16.8%/24.2%上行空间。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299809","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4526","BK4531","BK1161","09688","BK1574","BK1588","BK4139","BK4588","ZLAB","LU2488822045.USD","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629688951","title":"再鼎医药(09688.HK)：5月7日董事会审议及批准第一季度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2629688951","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629688951?lang=zh_cn&edition=full","pubTime":"2026-04-23 16:47","pubTimestamp":1776934021,"startTime":"0","endTime":"0","summary":"格隆汇4月23日丨再鼎医药公布，董事会审核委员会将于2026年5月7日(星期四)审议及批准根据美国公认会计准则及美国证券交易委员会的适用规则编制的公司及其附属公司截至2026年3月31日止三个月的未经审核季度业绩及其发布。　　在第一季度业绩获批准及发布后，公司管理层计划在2026年5月7日上午8:00/2026年5月7日下午8:00举行现场业绩电话会议及网络直播，以讨论第一季度业绩并回答提问。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260423/32167897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1161","BK4526","BK4139","BK1588","BK4531","BK4588","ZLAB","09688","LU2488822045.USD","BK4548","BK1574","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629303730","title":"再鼎医药(ZLAB)盘初跌超3% 此前录得6连阳累计涨幅达22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629303730","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629303730?lang=zh_cn&edition=full","pubTime":"2026-04-21 22:04","pubTimestamp":1776780260,"startTime":"0","endTime":"0","summary":"金吾财讯 | 再鼎医药(ZLAB)盘初股价出现回调，暂报24.485美元，跌幅3.03%。该股此前录得6连阳，累计涨幅达22%。四月至今累计涨幅超30%。消息面上，公司近日公布了ZL-1503临床前研究的最新数据，数据表明公司自主研发的这款IL-13/IL-31Rα双特异性抗体可能持续抑制特应性疾病引起的剧烈瘙痒和炎症。机构评级方面，坎托·菲茨杰拉德分析师Li Watsek维持再鼎医药“买入”评级，维持目标价37美元；摩根大通分析师Anupam Rama维持再鼎医药“买入”评级。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250107/ZjY1NDI1NzQxNDM1Mw==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/ZjY1NDI1NzQxNDM1Mw==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299518","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK4526","BK4531","BK1161","BK4548","BK4139","09688","BK4585","BK4588","ZLAB","BK1574","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628790399","title":"港股异动 | 再鼎医药(09688)涨超5% ZL-1503临床前研究的最新数据积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2628790399","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628790399?lang=zh_cn&edition=full","pubTime":"2026-04-20 09:45","pubTimestamp":1776649534,"startTime":"0","endTime":"0","summary":"消息面上，4月18日，再鼎医药公布了ZL-1503临床前研究的最新数据，数据表明公司自主研发的这款IL-13/IL-31Rα双特异性抗体可能持续抑制特应性疾病引起的剧烈瘙痒和炎症。该研究结果在马萨诸塞州波士顿举行的IMMUNOLOGY2026大会壁报展示环节发布，进一步证实了ZL-1503有望成为治疗中重度特应性皮炎及其他IL-13和IL-31驱动的疾病的同类首创疗法。据悉，再鼎医药于2025年12月启动了ZL-1503的首次人体1/1b期临床研究；临床数据预计于2026年下半年公布。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430466.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1588","BK1161","BK4585","BK4548","09688","LU2488822045.USD","BK4531","BK4526","VXUS","BK4139","ZLAB","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628202415","title":"热门中概股多股上扬 联电(UMC)领涨8.05% 小马智行(PONY)涨4.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628202415","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628202415?lang=zh_cn&edition=full","pubTime":"2026-04-17 22:08","pubTimestamp":1776434889,"startTime":"0","endTime":"0","summary":"金吾财讯 | 热门中概股多股上扬，联电(UMC)涨8.05%，小马智行(PONY)涨4.15%，再鼎医药(ZLAB)涨3.49%，万国数据(GDS)涨3.44%，拼多多(PDD)涨2.79%，金山云(KC)涨3.13%，亚玛芬体育(AS)涨2.69%，日月光半导体(ASX)涨2.43%，阿里巴巴(BABA)涨2.16%，台积电(TSM)涨2.16%。消息面上，近日摩根资产管理中国资深环球市场策略师朱超平表示，随着AI基建不断扩张，全球供应链对中国制造业的依赖程度在上升。目前，海外投资者对中国资产的确定性与认同性已大幅提升。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/Y2U1MTljZjZkNTgxMTYyODU5MDU0MTEzOA==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/Y2U1MTljZjZkNTgxMTYyODU5MDU0MTEzOA==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"299386","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868838027.USD","ASHS","LU2750360641.GBP","BK4581","IE00B5TLWC47.USD","LU2458330169.SGD","LU0561508036.HKD","LU1934455277.USD","LU2360108059.USD","LU0320764599.SGD","LU2106854487.HKD","LU2488822045.USD","LU0323591593.USD","LU1981816686.USD","ALBmain","LU0109392836.USD","LU0143863198.USD","BK4587","LU1989764748.USD","BK4607","TSM","LU2089283258.USD","LU2247934214.USD","LU0370786039.SGD","IE00BZ199S13.USD","LU1171460220.USD","LU2471134523.USD","LU0348827113.USD","LU1719994722.HKD","IE00BHPRN162.USD","LU0572940350.SGD","BK4558","BK4501","HK0000306701.USD","LU1868837722.USD","LU0384037296.USD","LU0737861772.HKD","LU2089284900.SGD","LU2054465674.USD","LU1688375341.USD","KBAB","LU0661504455.SGD","LU1989772840.SGD","LU0594300419.USD","LU0882747503.HKD","LU0158827781.USD","LU0348805143.USD","SGXZ51526630.SGD","LU1769817096.USD","IE00BFMHRM44.USD","LU2360106780.USD","LU0651947912.USD","BK4202","LU0348816934.USD","LU2237443622.USD","LU0348814723.USD","HXC","TSMU","LU0327786744.USD","LU1316542783.SGD","LU2087625088.SGD","LU0633140560.USD","BK4503","IE00BD6J9T35.USD","IE0004445239.USD","TSMY","LU2264538146.SGD","LU2491050071.SGD","IE00BQXX3D17.EUR","LU1868837565.USD","LU0456846285.SGD","LU0353189763.USD","AS","BK4532","LU1267930227.SGD","LU0117841782.USD","LU0106959298.USD","BK4550","LU2471134879.HKD","BK4534","SG9999004220.SGD","LU2506951792.HKD","IE0031814852.USD","HK0000320223.HKD","09988","LU2125154778.USD","BK4527","LU2458330243.SGD","LU0823426480.USD","LU1852331112.SGD","LU1823568750.SGD","LU0633140727.USD","IE00BFXG0V08.USD","LU0594300179.USD","LU0572944931.SGD","LU2250418816.HKD","09688","IE0004091025.USD","LU1037948897.HKD","LU0516423091.SGD","BK4139","LU2249611893.SGD","LU1046422090.SGD","IE00BQXX3F31.USD","BK4563","LU2226246903.HKD","LU0683595622.HKD","LU1008478684.HKD","LU0965508806.USD","SG9999001093.SGD","LU0545039389.USD","LU0264606111.USD","LU0072913022.USD","LU0823426308.USD","LU1051768304.USD","LU1251922891.USD","LU0541501648.USD","HK0000306685.HKD","LU0047713382.USD","LU2133065610.SGD","LU2357125470.USD","LU0198837287.USD","LU2041044095.USD","LU2008162690.USD","LU0094547139.USD","LU1989764664.SGD","LU0650527681.SGD","LU0488056044.USD","LU0140636845.USD","LU2028103732.USD","LU0056508442.USD","LU0039217434.USD","LU1934455194.USD","LU0572939691.SGD","LU0128525689.USD","LU0516423174.USD","LU1712237335.SGD","BK4531","LU2092937221.SGD","HK0000320264.USD","LU0738911758.USD","LU0516422952.EUR","LU2211815571.USD","LU0823397285.USD","LU1515016050.SGD","BK4524","LU0918141705.HKD","PDD","LU1235295612.USD","SG9999014674.SGD","TSMZ","LU0792757196.USD","LU0949170772.SGD","LU1037948541.HKD","LU1880383440.USD","LU1917777945.USD","LU2063271972.USD","LU2111349929.HKD","LU1934455863.HKD","LU2211814178.USD","LU0456842615.SGD","LU1105468828.SGD","LU0289960550.SGD","BK4533","LU0052756011.USD","LU0516422366.SGD","IE00BF5LJ272.USD","LU0588546209.SGD","LU1048588211.SGD","LU1051769294.HKD","BK4553","LU0417516902.SGD","BBYY","UMC","BK4504","LU0889566641.SGD","LU0871576103.HKD","LU0516422440.USD","LU0048580855.USD","IE00B29SXG58.USD","LU0231483743.USD","SG9999000418.SGD","LU0143863784.USD","IE00BYQQ9H92.USD","LU0345770308.USD","LU0589944569.HKD","LU2237443978.SGD","LU0164865239.USD","LU1794554557.SGD","LU1974910355.USD","LU0072462343.USD","SG9999002562.SGD","LU0158827948.USD","BK4220","LU2023250504.SGD","LU1211504680.USD","BK4023","CWEB","LU1508157978.USD","LU0359202008.SGD","IE0034224299.USD","LU2237443382.USD","BABO","LU0823414551.USD","BK4554","LU0979878070.USD","BK4614","LU1152091754.HKD","LU1003077747.HKD","LU0345770993.USD","LU0823397103.USD","IE00BGV7N243.SGD","ASX","LU2471134796.USD","LU1046421795.USD","BK4509","LU1267930813.SGD","LU1152091168.USD","LU0965509283.SGD","BK4591","LU0605514214.HKD","LU0823039010.USD","LU1235294995.USD","LU2271345857.HKD","02026","BK4116","LU0965509010.AUD","03145","LU2399975544.HKD","LU2279858448.HKD","LU0348788117.USD","BABW","LU0918141887.USD","LU0965509101.SGD","LU1769817179.HKD","LU0210526637.USD","LU0878005551.USD","LU1988902786.USD","IE0004086264.USD","BK4512","BK4585","BABU","BK1109","LU1956131251.USD","BK4526","LU0880133367.SGD","IE00BKPKM429.USD","PONY","LU0348825331.USD","LU2750360997.AUD","LU2257852520.SGD","TSMG","LU1803068979.SGD","LU0329678170.USD","LU1282648689.USD","LU2087589342.USD","ASHR","LU2211817866.USD","LU0329678337.USD","LU0307460666.USD","LU0797268264.HKD","LU0823421333.USD","PDDL","LU1064131342.USD","BK4605","BABX","LU0642271901.SGD","BK4608","LU0051755006.USD","BK4535","LU2860962120.EUR","DRAG","LU0502904849.HKD","LU0124676726.USD","LU0310800965.SGD","LU0359201885.HKD","KC","LU0821914370.USD","LU1023057109.AUD","LU0651946864.USD","BK4141","LU1323998911.USD","LU2663582299.SGD","LU0541502299.USD","LU1242518857.USD","LU1282649067.USD","LU0889565833.HKD","LU0823414478.USD","LU0082616367.USD","BK4575","LU1989772923.USD","LU0455707207.USD","LU2237443549.SGD","LU1323610961.USD","LU0963586101.USD","LU2491050154.USD","LU2125154935.USD","LU0531971595.HKD","IE00B3M56506.USD","LU1303224171.USD","BK4122","LU0251143458.SGD","LU0823038988.USD","09698","LU0456827905.SGD","LU2543165471.USD","LU0348723411.USD","LU0823421416.USD","BK4588","SGXZ81514606.USD","LU0328353924.USD","STSM","LU0878004406.USD","LU1720050803.USD","LU1770034418.SGD","LU1808992512.USD","BK4548","LU0259732245.USD","LU0067412154.USD","LU0823413660.USD","LU0501845795.SGD","LU0052750758.USD","BK4565","KPDD","LU0175139822.USD","LU2491049909.HKD","LU1282649810.SGD","LU1623119135.USD","GDS","BK4579","LU2471134952.CNY","LU2298321311.HKD","LU0316494557.USD","03896","LU0353189680.USD","LU1961090484.USD","ZLAB","LU1048596156.SGD","LU2242644610.SGD","LU0708995583.HKD","MCHI","BK4602","LU0553294199.USD","LU0689626769.HKD","LU0238689110.USD","LU0719512351.SGD","LU2023251221.USD","BK4538","BABA","LU2148611432.USD","LU0359201612.USD","BK4502","LU0861579265.USD","IE00BQXX3C00.GBP","LU1242518931.SGD","BK4529","BK4543","LU2039709279.SGD","LU2294711713.HKD","BK4612","SGXZ99366536.SGD","IE00B0JY6N72.USD","LU0315179316.USD","SG9999002828.SGD","LU2360032135.SGD","LU0823413587.USD","LU2177674079.SGD","LU1880383366.USD","BK4505","LU0049112450.USD","LU0235996351.USD","SG9999002463.SGD","TSMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627219520","title":"再鼎医药(09688.HK)遭摩根大通减持170.74万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2627219520","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627219520?lang=zh_cn&edition=full","pubTime":"2026-04-16 21:57","pubTimestamp":1776347821,"startTime":"0","endTime":"0","summary":"格隆汇4月16日丨根据联交所最新权益披露资料显示，2026年4月13日，再鼎医药(09688.HK)遭JPMorgan Chase & Co.以每股均价16.2495港元减持好仓170.74万股，涉资约2774.45万港元。\r\n\r\n　　减持后，JPMorgan Chase & Co.最新持好仓数目为77,967,965股，持好仓比例由7.02%下降至6.87%。","market":"us","thumbnail":" http://caiji.3g.cnfol.com/colect/202604/16/20260416992297.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202604/16/20260416992297.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260416/32149326.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["LU0238689110.USD","LU2237443382.USD","SG9999002232.USD","LU0211327993.USD","LU1668664300.SGD","LU1988902786.USD","LU0971096721.USD","LU2023250330.USD","BK4585","LU0203347892.USD","LU0234572021.USD","LU1496350502.SGD","LU0868494617.USD","LU0345769128.USD","LU1894683348.USD","LU1280957306.USD","LU2106854487.HKD","LU0211326755.USD","LU0170899867.USD","LU2746668974.SGD","LU0787776722.HKD","LU1551013342.USD","JPO","BK1574","LU0203345920.USD","LU2746668461.USD","LU0106261372.USD","LU0320765646.SGD","IE000M9KFDE8.USD","LU0345769631.USD","LU0006306889.USD","IE00BJTD4V19.USD","BK1588","LU0265550359.USD","LU2237443622.USD","LU0267386448.USD","LU0208291251.USD","ZLAB","LU1244550221.USD","LU0882574139.USD","IE0034235303.USD","BK4534","LU0211328371.USD","JPMO","LU0964807845.USD","BK4504","LU2237443895.HKD","LU0211331839.USD","LU2213496289.HKD","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627025713","title":"港股异动 | 再鼎医药(09688)涨超4% 宣布与勃林格殷格翰合作开发创新双DLL3靶向药物联合疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2627025713","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627025713?lang=zh_cn&edition=full","pubTime":"2026-04-16 10:09","pubTimestamp":1776305396,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超4%，截至发稿，涨3.84%，报18.1港元，成交额8271.49万港元。消息面上，4月15日，据再鼎医药官微消息，公司与勃林格殷格翰宣布一项临床合作，着力开发一种创新的双DLL3靶向药物联合疗法。Ib/II期研究将评估再鼎医药的靶向DLL3的ADC zocilurtatug pelitecan与勃林格殷格翰的DLL3/CD3 T细胞衔接器obrixtamig联合使用的安全性、耐受性及初步临床活性。据介绍，Zocilurtatug pelitecan是再鼎医药开发的一款靶向DLL3的ADC，旨在向DLL3阳性肿瘤细胞递送强效细胞毒性载荷，用于ES-SCLC治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429188.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","09688","BK4585","VXUS","BK1588","BK4526","BK4588","BK4139","BK4548","ZLAB","BK4531","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627230698","title":"纳斯达克中国金龙指数收涨0.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2627230698","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627230698?lang=zh_cn&edition=full","pubTime":"2026-04-16 04:17","pubTimestamp":1776284255,"startTime":"0","endTime":"0","summary":"嘉楠科技涨8.29%，Tims中国涨6.28%，再鼎医药涨5.74%，BOSS直聘涨5.52%，知乎涨4.85%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604163706460923.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604163706460923.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK4535","02390","BK4170","BZ","LU2039709279.SGD","BK4505","02076","BK4595","IE00B29SXG58.USD","LU0359201612.USD","LU1688375341.USD","BK4509","BK4551","HXC","ZLAB","BK4588","BK4526","BK4077","09688","BK1161","HK0000252160.HKD","CAN","ZH","HK0000252152.HKD","BK1095","LU1023057109.AUD","NDX","BK4563",".IXIC","HK0000500386.USD","BK1588","BK4130","BK4585","BK4503","BK4539","BK4600","LU0359202008.SGD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627498112","title":"港股异动 | 再鼎医药(09688)涨超3% 近日与安进达成全球临床合作 Zoci正处于全球注册性临床III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2627498112","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627498112?lang=zh_cn&edition=full","pubTime":"2026-04-14 09:46","pubTimestamp":1776131184,"startTime":"0","endTime":"0","summary":"消息面上，近日，再鼎医药官微宣布，公司与安进公司达成一项全球临床研究合作，旨在评估再鼎医药处于临床阶段的靶向delta样配体3的抗体药物偶联物zocilurtatug pelitecan联合安进IMDELLTRA，一款靶向DLL3的双特异性T细胞衔接器疗法，用于治疗广泛期小细胞肺癌患者。作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428082.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE0002141913.USD","LU1571399168.USD","LU2468319806.SGD","LU1061106388.HKD","LU2242652126.USD","IE00B4R5TH58.HKD","BK1161","LU0320765992.SGD","09688","LU0868494617.USD","AMGN","LU1023059063.AUD","BK4599","BK4526","VXUS","IE00BFTCPJ56.SGD","LU2112291526.USD","ZLAB","LU0289739699.SGD","BK4581","LU1983299246.USD","LU1057294990.SGD","SG9999001440.SGD","IE00B2B36J28.USD","LU2242646821.SGD","BK4566","BK4531","BK4134","BK1574","LU0058720904.USD","LU0889565916.HKD","BK4588","IE00BJJMRZ35.SGD","BK4139","BK4533","LU0109394709.USD","LU2488822045.USD","IE00BJT1NW94.SGD","BK1588","BK4585","III","LU0122379950.USD","BK4548","IE0009355771.USD","BK4534","LU2089984988.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624005385","title":"再鼎医药(09688)授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2624005385","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624005385?lang=zh_cn&edition=full","pubTime":"2026-04-02 22:49","pubTimestamp":1775141352,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于2026年4月1日(美国东部时间)根据2024年股权激励计划授出部分购股权、受限制股份单位以及业绩股份单位。授出可认购26.85万股美国存托股份的购股权、60.3851万股美国存托股份受限制股份单位及33,781股美国存托股份的业绩股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1424881.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4588","09688","BK4139","BK4531","BK4526","BK4548","LU2488822045.USD","BK4585","ZLAB","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624222315","title":"再鼎医药宣布达成全球临床研究合作及供应协议，以评估创新性DLL3抗体药物偶联物Zocilurtatug Pelitecan与双特异性T细胞衔接器的联合治疗","url":"https://stock-news.laohu8.com/highlight/detail?id=2624222315","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624222315?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:58","pubTimestamp":1775102280,"startTime":"0","endTime":"0","summary":"再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。\" Zoci是靶向DLL3的 ADC，用于小细胞肺癌的治疗。关于Zocilurtatug Pelitecan  Zoci是再鼎医药全球肿瘤研发管线中一款靶向DLL3的新型ADC。Zoci已获得美国FDA授予的治疗SCLC的孤儿药资格认定和快速通道资格认定。IMDELLTRA是首款靶向DLL3的双特异性T细胞衔接器疗法，在上述患者中已验证具有总生存期获益。Zocilurtatug Pelitecan与IMDELLTRA的联合用药方案有望在此优势基础上，进一步改善有效性，同时保持可控的安全性[6]。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4924934_ZH24934_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4526","BK1161","BK4588","BK4139","BK1574","BK4531","BK4548","LU2488822045.USD","09688","BK4585","ZLAB","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624524927","title":"再鼎医药午前涨近5% 与安进公司达成一项全球临床研究合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2624524927","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624524927?lang=zh_cn&edition=full","pubTime":"2026-04-02 11:37","pubTimestamp":1775101020,"startTime":"0","endTime":"0","summary":"　　再鼎医药午前涨超4%，截至发稿，股价上涨4.82%，现报15.88港元，成交额2.88亿港元。　　作为该合作协议的一部分，安进将申办一项全球1b期研究，评估zoci联合IMDELLTRA在ES-SCLC患者中的安全性和有效性。再鼎医药将保留zoci的完整所有权，并将向安进提供临床研究用药。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-04-02/doc-inhtaraa1102717.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1983299246.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","BK4534","LU0058720904.USD","LU2468319806.SGD","LU2112291526.USD","BK4531","IE0002141913.USD","BK4585","AMGN","LU1023059063.AUD","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","BK4566","BK4526","IE0009355771.USD","IE00BJT1NW94.SGD","LU0889565916.HKD","LU0868494617.USD","LU0122379950.USD","BK4139","09688","LU0109394709.USD","LU1057294990.SGD","BK1574","LU2089984988.USD","BK4581","LU2488822045.USD","LU2242652126.USD","BK4548","ZLAB","LU0320765992.SGD","BK1588","BK1161","LU0289739699.SGD","LU2242646821.SGD","LU1571399168.USD","BK4533","BK4599","IE00BJJMRZ35.SGD","LU1061106388.HKD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624452674","title":"港股再鼎医药涨超4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624452674","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624452674?lang=zh_cn&edition=full","pubTime":"2026-04-02 09:58","pubTimestamp":1775095138,"startTime":"0","endTime":"0","summary":"每经AI快讯，4月2日，再鼎医药(09688.HK)涨超4%，截至发稿涨4.22%，报15.79港元，成交额9800.73万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604023693054050.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":"6c2eecd8186c1b91dbc836fcc084ea03","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604023693054050.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["VXUS","BK1588","BK4588","09688","BK4139","BK4531","BK4526","BK4548","LU2488822045.USD","BK4585","ZLAB","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622570897","title":"再鼎医药(09688)发布年度业绩 总收入同比增加15%至4.6亿美元 各产品管线进展积极","url":"https://stock-news.laohu8.com/highlight/detail?id=2622570897","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622570897?lang=zh_cn&edition=full","pubTime":"2026-03-27 07:20","pubTimestamp":1774567240,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药 发布截至2025年12月31日止财政年度全年业绩，产品收入净额增加15%至4.57亿美元，主要是由于鼎优乐的销售增加及纽再乐的销售增加。每股基本及摊薄亏损为0.16美元。于2025年，公司的财务业绩持续强势，总收入较上年增加15%至4.6亿美元，而净亏损则减少32%至1.76亿美元。于2026年，公司预计收入将持续增长，主要得益于现有商业化产品以及近期获批并预计于今年内上市的产品或新适应证。公司的各产品管线方面亦继续取得进展。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1420133.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"再鼎医药(09688)发布年度业绩 总收入同比增加15%至4.6亿美元 各产品管线进展积极","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","BK1161","BK4139","BK4585","09688","BK1588","BK4526","BK4548","LU2488822045.USD","ZLAB","BK4531"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619546907","title":"再鼎医药(09688.HK)拟3月26日(美国东部时间)/3月27日(香港时间)举行董事会会议以审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2619546907","media":"中金财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619546907?lang=zh_cn&edition=full","pubTime":"2026-03-16 22:07","pubTimestamp":1773670021,"startTime":"0","endTime":"0","summary":"格隆汇3月16日丨再鼎医药(09688.HK)公告，董事会将于2026年3月26日(星期四，美国东部时间)/2026年3月27日(星期五，香港时间)审议及批准(其中包括)根据香港联合交易所有限公司证券上市规则编制的公司及其附属公司截至2025年12月31日止年度的年度业绩及其发布。\r\n\r\n　　公司先前已公布其根据美国公认会计准则编制的年度业绩，并于2026年2月26日(星期四，美国东部时间/香港时间)以表格10-K向美国证券交易委员会(\"美国证交会\")提交其截至2025年12月31日止年度的年度报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260316/32072706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK4139","BK1574","BK1161","BK1588","LU2488822045.USD","BK4588","BK4526","BK4531","BK4548","BK4585","ZLAB","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619190413","title":"再鼎医药(09688)：授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2619190413","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619190413?lang=zh_cn&edition=full","pubTime":"2026-03-13 21:24","pubTimestamp":1773408240,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，本公司于授出日期根据2024年股权激励计划授出35.34万份购股权、3.24万股受限制股份单位以及17.54万股业绩股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1413883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1161","BK4548","BK1588","BK4139","BK4585","BK4531","ZLAB","BK4588","BK4526","09688","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618862761","title":"再鼎医药(09688)授出购股权、受限制股份单位及业绩股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2618862761","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618862761?lang=zh_cn&edition=full","pubTime":"2026-03-09 22:42","pubTimestamp":1773067323,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于授出日期根据2024年股权激励计划授出可认购37.422万股美国存托股份的购股权、12.162万股美国存托股份受限制股份单位以及18.2428万股美国存托股份的业绩股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411864.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2488822045.USD","09688","BK1161","BK1588","BK4139","BK4526","BK4548","ZLAB","BK4588","BK1574","BK4585","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617526522","title":"再鼎医药(09688)授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2617526522","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617526522?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:54","pubTimestamp":1772722453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于授出日期根据2024年股权激励计划向4名承授人授出可认购合共8万股美国存托股份的购股权并向9名承授人授出涉及合共12.344万股美国存托股份的受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410705.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4139","BK4531","BK1588","LU2488822045.USD","BK4526","BK1574","BK4548","BK4588","09688","BK1161","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617752571","title":"再鼎医药(09688)：Moulder已调任董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2617752571","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617752571?lang=zh_cn&edition=full","pubTime":"2026-03-05 22:39","pubTimestamp":1772721583,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，Leon O. Moulder, Jr.先生已调任公司董事，自本公告之日起生效。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1410700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1574","BK4139","BK4548","BK1588","LU2488822045.USD","BK4526","BK1161","BK4531","09688","ZLAB","BK4585"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":0.1505},{"period":"3month","weight":0.3036},{"period":"6month","weight":-0.1718},{"period":"1year","weight":-0.3171},{"period":"ytd","weight":0.2268}],"compareEarnings":[{"period":"1week","weight":0.0144},{"period":"1month","weight":0.1051},{"period":"3month","weight":0.0386},{"period":"6month","weight":0.0537},{"period":"1year","weight":0.296},{"period":"ytd","weight":0.0539}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.085823},{"month":2,"riseRate":0.555556,"avgChangeRate":0.030708},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.076257},{"month":4,"riseRate":0.444444,"avgChangeRate":0.02394},{"month":5,"riseRate":0.5,"avgChangeRate":0.028309},{"month":6,"riseRate":0.5,"avgChangeRate":0.075433},{"month":7,"riseRate":0.5,"avgChangeRate":0.004927},{"month":8,"riseRate":0.625,"avgChangeRate":0.000651},{"month":9,"riseRate":0.375,"avgChangeRate":-0.055585},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.047464},{"month":11,"riseRate":0.555556,"avgChangeRate":0.101421},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.029495}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}